Literature DB >> 13988398

A comparison of the use of Aldactone and Aldactone A in the treatment of hepatic ascites.

S SHALDON, J A RYDER, M GARSENSTEIN.   

Abstract

In eight patients with cirrhosis and stable ascites controlled on chlorothiazide and spironolactone, a small particle preparation of spironolactone (Aldactone A) was as effective, at one quarter the dosage, as conventional spironolactone (Aldactone). Plasma spironolactone metabolite levels and urinary excretion of spironolactone metabolite were equivalent with both preparations. The variable dosage requirement of spironolactone in patients with cirrhosis and ascites is discussed in relation to these observations.

Entities:  

Keywords:  ASCITES; CHLOROTHIAZIDE; LIVER CIRRHOSIS; SPIRONOLACTONE

Mesh:

Substances:

Year:  1963        PMID: 13988398      PMCID: PMC1413409          DOI: 10.1136/gut.4.1.16

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  7 in total

1.  [Treatment of ascites in patients with liver cirrhosis].

Authors:  S SHALDON; S SHERLOCK
Journal:  Med Klin       Date:  1962-08-03

2.  Effect of a detergent on gastrointestinal absorption of a steroid.

Authors:  C L GANTT; N GOCHMAN; J M DYNIEWICZ
Journal:  Lancet       Date:  1961-03-04       Impact factor: 79.321

3.  Combined diuretic and steroid therapy in cirrhosis with ascites.

Authors:  R S MORRISON; T C CHALMERS
Journal:  Ann N Y Acad Sci       Date:  1960-10-11       Impact factor: 5.691

4.  The clinical application of aldosterone antagonists in the treatment of oedema.

Authors:  S SHALDON
Journal:  Proc R Soc Med       Date:  1961-04

5.  Treatment of "refractory" ascites with a new aldosterone antagonist in patients with cirrhosis.

Authors:  B F CLOWDUS; J A HIGGINS; J W ROSEVEAR; W H SUMMERSKILL
Journal:  Proc Staff Meet Mayo Clin       Date:  1960-03-02

6.  Resistant ascites treated by combined diuretic therapy (spironolactone, mannitol, and chlorothiazide).

Authors:  S SHALDON; J R McLAREN; S SHERLOCK
Journal:  Lancet       Date:  1960-03-19       Impact factor: 79.321

7.  A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma.

Authors:  N GOCHMAN; C L GANTT
Journal:  J Pharmacol Exp Ther       Date:  1962-03       Impact factor: 4.030

  7 in total
  5 in total

1.  The aetiology and management of ascites in patients with hepatic cirrhosis: a review.

Authors:  S SHERLOCK; S SHALDON
Journal:  Gut       Date:  1963-06       Impact factor: 23.059

2.  Antagonism of fludrocortisone by spironolactone and canrenone.

Authors:  G J Huston; P Turner
Journal:  Br J Clin Pharmacol       Date:  1976-02       Impact factor: 4.335

3.  Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.

Authors:  W Sadée; R Schröder; E von Leitner; M Dagcioglu
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

4.  Pharmacokinetics of the new aldosterone antagonist, spirorenone, in healthy volunteers after single and repeated daily doses.

Authors:  W Krause; C Sack; W Seifert
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency.

Authors:  G T McInnes; I R Harrison; J R Shelton; R M Perkins
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.